Inotiv, Inc.
Fundamentals are temporarily unavailable for NOTV.
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $547.66M | $572.42M | $490.74M | $513.02M |
| Cost of Revenue | $390.44M | $390.48M | $379.57M | $392.04M |
| Gross Profit | $157.21M | $181.94M | $111.17M | $120.98M |
| Selling, General & Admin | $99.09M | $123.78M | $97.92M | $92.24M |
| Operating Expenses | $136.96M | $191.18M | $165.63M | $157.98M |
| Operating Income | $20.25M | -$9.24M | -$54.46M | -$37.00M |
| EBITDA | -$273.42M | -$26.51M | -$26.76M | $24.75M |
| Pretax Income | -$352.45M | -$124.24M | -$130.76M | -$87.77M |
| Income Tax | -$15.19M | -$19.34M | -$21.88M | -$19.14M |
| Net Income | -$337.02M | -$105.14M | -$108.44M | -$68.63M |
| Diluted EPS | -13.84 | -4.10 | -4.19 | -2.11 |
| Diluted Shares | 24.35M | 25.64M | 25.90M | 32.45M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $18.52M | $35.49M | $21.43M | $21.74M |
| Receivables | $100.44M | $90.42M | $77.44M | $97.45M |
| Inventory | $71.44M | $56.10M | $18.17M | $45.74M |
| Current Assets | $232.98M | $213.80M | $163.41M | $194.59M |
| Total Assets | $962.90M | $856.53M | $781.36M | $771.11M |
| Current Liabilities | $164.10M | $132.19M | $119.04M | $556.78M |
| Long-Term Debt | $330.68M | $369.80M | $389.80M | — |
| Total Debt | $386.49M | $417.64M | $445.77M | $459.29M |
| Total Liabilities | $603.13M | $588.04M | $610.86M | $635.09M |
| Retained Earnings | -$348.28M | -$453.28M | -$562.16M | -$630.81M |
| Shareholders' Equity | $360.37M | $269.15M | $170.50M | $136.03M |
| Working Capital | $68.88M | $81.61M | $44.37M | -$362.19M |
| Net Debt | $335.14M | $342.25M | $371.91M | $383.38M |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | -$5.22M | $27.88M | -$6.80M | -$10.46M |
| Capital Expenditure | -$36.30M | -$27.50M | -$22.31M | -$16.61M |
| Free Cash Flow | -$41.52M | $380.00K | -$29.11M | -$27.07M |
| Depreciation & Amortisation | $49.32M | $54.72M | $57.12M | $55.93M |
| Stock-Based Compensation | $24.20M | $7.84M | $6.74M | $6.03M |
| Investing Cash Flow | -$333.72M | -$28.75M | -$16.83M | -$12.89M |
| Financing Cash Flow | $203.15M | $15.87M | $9.68M | $23.70M |
| Net Change in Cash | -$135.79M | $15.00M | -$13.96M | $355.00K |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue | $124.32M | $130.68M | $138.14M | $120.88M | $117.65M |
| Cost of Revenue | $95.33M | $96.76M | $105.11M | $96.07M | $93.00M |
| Gross Profit | $28.99M | $33.92M | $33.03M | $24.81M | $24.65M |
| Selling, General & Admin | $22.23M | $23.41M | $22.32M | $23.91M | $23.31M |
| Operating Expenses | $38.47M | $39.45M | $39.73M | $40.95M | $41.77M |
| Operating Income | -$9.48M | -$5.53M | -$6.71M | -$16.14M | -$17.13M |
| EBITDA | $11.29M | $8.83M | $6.42M | -$2.76M | -$5.60M |
| Pretax Income | -$15.98M | -$18.76M | -$23.22M | -$30.02M | -$33.74M |
| Income Tax | -$1.11M | -$1.19M | -$14.67M | -$1.64M | -$1.28M |
| Net Income | -$14.87M | -$17.58M | -$8.55M | -$28.38M | -$32.47M |
| Diluted EPS | -0.44 | -0.51 | -0.25 | -0.83 | -0.94 |
| Diluted Shares | 33.99M | 34.35M | 34.35M | 34.37M | 34.65M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $19.30M | $6.21M | $21.74M | $12.73M | $15.18M |
| Receivables | $74.35M | $91.85M | $97.45M | $88.54M | $74.70M |
| Inventory | $38.04M | $45.07M | $45.74M | $44.32M | $30.55M |
| Current Assets | $173.66M | $175.59M | $194.59M | $163.77M | $144.47M |
| Total Assets | $765.97M | $759.74M | $771.11M | $734.34M | $702.42M |
| Current Liabilities | $115.41M | $136.60M | $556.78M | $538.54M | $540.28M |
| Long-Term Debt | $392.39M | $390.34M | — | — | — |
| Total Debt | $451.59M | $448.21M | $459.29M | $475.97M | $487.77M |
| Total Liabilities | $608.27M | $615.95M | $635.09M | $625.31M | $625.32M |
| Retained Earnings | -$604.68M | -$622.26M | -$630.81M | -$659.19M | -$691.66M |
| Shareholders' Equity | $157.69M | $143.78M | $136.03M | $109.02M | $77.10M |
| Working Capital | $58.25M | $38.99M | -$362.19M | -$374.77M | -$395.82M |
| Net Debt | $380.24M | $390.33M | $383.38M | $399.04M | $408.24M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.81M | -$7.45M | $14.30M | -$5.43M | -$1.07M |
| Capital Expenditure | -$5.47M | -$4.01M | -$2.68M | -$5.18M | -$2.10M |
| Free Cash Flow | -$18.29M | -$11.45M | $11.63M | -$10.61M | -$3.17M |
| Depreciation & Amortisation | $13.82M | $13.98M | $13.94M | $13.79M | $14.08M |
| Stock-Based Compensation | $1.44M | $1.44M | $1.38M | $1.38M | $1.20M |
| Investing Cash Flow | -$5.45M | -$2.51M | -$475.00K | -$5.18M | -$2.10M |
| Financing Cash Flow | -$632.00K | -$3.41M | $1.62M | $1.54M | $5.89M |
| Net Change in Cash | -$18.90M | -$13.36M | $15.45M | -$9.08M | $2.72M |
Market Snapshot
About
Inotiv is a contract research organization providing nonclinical and analytical drug discovery and development services to pharmaceutical and biotech companies.